MEK162, MEK inhibitor; oral + Physician's choice chemotherapy
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Low-grade Serous Ovarian Cancer
Conditions
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Trial Timeline
Jun 27, 2013 → Aug 23, 2022
NCT ID
NCT01849874About MEK162, MEK inhibitor; oral + Physician's choice chemotherapy
MEK162, MEK inhibitor; oral + Physician's choice chemotherapy is a phase 3 stage product being developed by Pfizer for Low-grade Serous Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01849874. Target conditions include Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Low-grade Serous Ovarian Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01849874 | Phase 3 | Terminated |
Competing Products
13 competing products in Low-grade Serous Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 26 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Everolimus | Novartis | Phase 2 | 35 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 35 |
| rituximab | Biogen | Phase 3 | 37 |
| Tovorafenib | Ipsen | Phase 1 | 33 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 36 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 41 |
| DAY101 | Day One Biopharmaceuticals | Phase 1 | 23 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 20 |
| TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD | Tyra Biosciences | Phase 2 | 36 |
| rhuFlt3L/CDX-301 + Poly-ICLC | Celldex Therapeutics | Phase 1/2 | 26 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 25 |